Drug therapy of dementia in elderly patients. A review

References

• Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV.Pharmacological treatment and agitation in elderly patients with dementia: Four decades of experience. Drugs Aging 2002;19: 257–/76.
   Google Scholar
• Street JS, Clark WS, Kadam DL, Mitan SJ, Julian BE, Feldman PD, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in nursing home patients with Alzheimer–s dementia. Int J Geriatric Psychiatry 2001;16: 562–/70.
   Google Scholar
• The ICD-10 classification of mental and behavioural disorders. Geneva: WHO; 1992.
   Google Scholar
• Jacoby R, Oppenheimer C (editors). Psychiatry in the elderly. Oxford: Oxford University Press; 2002.
   Google Scholar
• Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. London: Martin Dunitz; 1999.
   Google Scholar
• Matzen P. Evidence-based medicine. In: Lorenzen I, Bendixen G, Hansen NE, editors. Textbook of medicine [Medicinsk kompendium]. Nyt Nordisk Forlag Arnold Busk, Copenhagen: 1999. p. 12–/23.
   Google Scholar
• Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Mo– ller H-J, et al. The effects of donepezil in Alzheimer –s disease –/ Results from a multinational trial. Dement Geriatr Cogn Disord 1999;10: 237–/44.
   Google Scholar
• Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer–s disease. Dement Geriatr Cogn Disord 2000;11: 299–/313.
   Google Scholar
• Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer–s disease: A randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71: 589–/95.
   Google Scholar
• Farlow M, Anand R, Jr Messina J, Hartman R, Veach J. A 52- week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer–s disease. Eur Neurol 2000;44: 236–/ 41.
   Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju V, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer–s disease combined with cerebrovascular disease: A randomised trial. Lancet 2002;359: 1283–/90.
   Google Scholar
• Mo–bius J. H., Sto– ffler A. New approaches to clinical trials in vascular dementia: Memantine in small vessel disease. Cerebrovasc Dis 2002;13 Suppl 2:61–/6.
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD A 6-month randomised, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–/8.
   Google Scholar
• Wilcock KG, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer–s disease: Multi-centre randomised controlled trial. BMJ 2000;321: 1445 –/9.
   Google Scholar
• Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomised, placebo-controlled trial of Galantamine in AD. Neurology 2000;54: 2269–/76.
   Google Scholar
• Ro– sler M, Anand R, Cicin-Sain A, Gauthier S, Agid, Dal-Bianco P, Stahelin HB, et al. Efficacy and safety of rivastigmine in patients with Alzheimer–s disease: International randomised controlled trial. BMJ 1999;318: 633–/8.
   Google Scholar
• Wilcock G, Mo–bius HJ, Sto– ffler. A double blind, placebo-controlled multi-centre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17: 297–/305.
   Google Scholar
• Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, et al. A 24-week, randomised, double blind study of donepezil in moderate to severe Alzheimer–s disease. Neurology 2001;57: 613–/20.
   Google Scholar
• Wilkinson D, Murray J. Galantamine: A randomised, double blind, dose comparison in patients with Alzheimer–s disease. Int J Geriatr Psychiatry 2001;16: 852–/7.
   Google Scholar
• Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57: 489–/95.
   Google Scholar
• Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57: 481–/8.
   Google Scholar
• Orgogozo MJ, Rigaud SA, Sto– ffler A, Mo–bius JH, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 2002;33: 1834–/9.
   Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24- week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer–s disease. Neurology 1998;50: 136–/45.
   Google Scholar
• Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. ArzneimittelsForsch Drug Res 1991;41: 773–/ 80.
   Google Scholar
• Rogers LS, Friedhoff TL, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer–s disease: Results of a US multi-centre, randomised, double-blind, placebo-controlled trial. Dementia 1996;7: 293 –/303.
   Google Scholar
• Tariot N, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomised, double blind, placebocontrolled study of the efficacy and safety of donepezil in patients with Alzheimer–s disease in the nursing home setting. JAGS 2001;49: 1590–/9.
   Google Scholar
• Gauthier S, Feldman H, Hecher J, Vallas B, Emir B, Subbiah P. Functional, cognitive and behavioural effects of donepezil in patients with moderate Alzheimer–s disease. Curr Med Res Opin 2002;18: 347–/54.
   Google Scholar
• Scharon RL, Doody RS, Mohs RC, Lawrence FT. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998;158: 1021 –/31.
   Google Scholar
• McKeith I, Ser TD, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double blind placebo-controlled international study. Lancet 2000;356:2031 –/6.
   Google Scholar
• Winblad B, Pontis N. Memantine in severe dementia: Results of the M-best study, benefit and efficacy in severely demented patients during treatment with memantine. Int J Geriat Psychatr 1999;14: 135–/45.
   Google Scholar
• Reisberg B, Doody R, Sto– ffler A, Schmitt F, Ferris S, Mo–bius HJ. Memantine in moderate-to-severe Alzheimer–s disease. New Eng J Medicine 2003;348: 1333 –/41.
   Google Scholar
• Greenberg MS, Tennis KM, Brown BL, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice. Arch Neurol 2000;57: 94–/9.
   Google Scholar
• Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Pratt RD. Donepezil in vascular dementia. Neurology 2003;61: 479–/86.
   Google Scholar
• Olin J, Schneider L. Galantamine for Alzheimer–s disease (Cochrane Review). Oxford: Update Software; 2002.
   Google Scholar
• Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer–s disease (Cochrane Review). Oxford: Update Software; 2002.
   Google Scholar
• Birks J, Grimley, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer–s disease (Cochrane Review). Oxford: Update Software; 2002.
   Google Scholar
• Sastre A, Sherriff F. Memantine for dementia (Cochrane Review).Oxford: Update Software; 2003.
   Google Scholar
• Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FCV, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer–s disease. IJCP 2002;56: 441–/6.
   Google Scholar
• Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer–s disease. Drugs Aging 2003;20: 777–/89.
   Google Scholar
• Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer–s disease (AD200): Randomised double-blind trial. Lancet 2004;363:2101 –/15.
   Google Scholar